ClinicalTrials.gg
Active, not recruitingNCT02455531SVRIIIUpdated Nov 10, 2025Results posted

Long-term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type

An observational study in Heart Defects, sponsored by Carelon Research. Active, not recruiting. Open to participants aged 10 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Carelon Research · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
237
Ages
10 Years to 12 Years
Sex
All
01

Study summary

The purpose of this study is to compare direct and indirect measures of right ventricular (RV) systolic and diastolic function between 11 year old subjects who had been randomly assigned to receive a right ventricle to pulmonary artery shunt (RVPAS) vs. a modified Blalock-Taussig shunt (MBTS) at the time of the Norwood operation.

Read the detailed description

The Single Ventricle Reconstruction (SVR) trial was the first multicenter, randomized clinical trial to compare two operations in the field of congenital heart disease.8,11 Children with HLHS and other related single RV lesions were enrolled and randomized to receive either a MBTS or a RVPAS at the time of the initial Norwood procedure. This landmark study provided extraordinary insight not only into the consequences of both shunt types, but also into the course, treatment responses and short- and mid-term outcomes for these medically complex patients. Through the SVR Trial and SVR Extension Study (SVR II), outcomes, including but not limited to the primary outcome of transplant-free survival, have now been evaluated in this patient cohort when the last enrolled patient reached 12 months and again at 3 years of age. While early post-operative transplant-free survival during the interstage period7 and at one year8 was better for those children randomized to a RVPAS, survival by the 3-year evaluation appeared equivalent between the two shunt types. Moreover, RVEF was somewhat diminished and the number of interventions was higher in the RVPAS group.12 These findings raised concern that the RV dysfunction in the RVPAS group may be progressive, leading to significantly worse long-term outcomes; if so, the benefits of the RVPAS for short-term survival may be outweighed by longer-term morbidity and mortality. Thus, the optimal surgical approach for newborns with HLHS and related single RV lesions remains unclear.

The Pediatric Heart Network (PHN) Investigators have a unique opportunity and responsibility to analyze the effect of the type of systemic-to-pulmonary artery shunt placed during the Norwood procedure on longer-term survival, as well as to define its effect on other long-term outcomes in this multi-institutional cohort of exquisitely characterized subjects with single RV lesions. As subjects enrolled in the SVR cohort approach a decade of age, the investigators aim: 1) to determine if shunt type at the time of Norwood operation is associated with any long-term differences in cardiac function, survival, or contributors to quality of life; and 2) to characterize long-term outcomes and determine risk factors other than shunt type for adverse long-term outcomes in children with HLHS and other related single ventricle anomalies.

02

Conditions studied

  • Heart Defects
03

In context

Lead sponsor

Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All SVR study cohort members will be contacted to assess for vital status. Transplant free survivors will be approached to participate in the in-person assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All SVR study cohort members will be contacted to assess for vital status. Transplant free survivors will be approached to participate in the in-person assessment.

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone cardiac transplantation or biventricular conversion from all outcomes other than vital status.
  • Those with pacemakers will be excluded from the CMR, and patients \<130 cm in height will be excluded from the exercise test.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
237 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Transplant-free survivors

    Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)

06

What researchers measure

Primary outcomes

  1. RVEF at 10-12 Years on MRI

    RV ejection fraction (RVEF) at 10-12 years, as measured by cardiac magnetic resonance (CMR).

    Time frame: assessed between 10-12 years of age, an average of 53.2 days from consent

Secondary outcomes

  1. Death or Cardiac Transplantation

    The incidence of death or cardiac transplantation between those randomized to receive a RVPAS vs. a MBTS at the time of the Norwood operation.

    Time frame: 11 years ± 1 year to 16 years

  2. The Exercise Tolerance Between Those Randomized to a RVPAS vs. a MBTS.

    Exercise capacity: Maximal Oxygen Consumption (VO2max), maximal work rate, and anaerobic threshold

    Time frame: 11 years ± 1 year to 16 years

  3. Atrial and Ventricular Arrhythmias

    The incidence of arrhythmias between those randomized to a RVPAS vs. a MBTS.

    Time frame: 11 years ± 1 year to 16 years

  4. The Neurodevelopmental Outcomes at 11 Years of Age in Those Randomized to a RVPAS vs. a MBTS

    Achievement, as measured by the Wechsler Individual Achievement Tests (WIAT) (Math and Reading); Intelligence, as measured by the Wechsler Intelligence Scale for Children (WISC); Other domains of neurodevelopmental function including assessment of language, executive function, visual spatial skills, motor function, memory, social skills, behavior, health-related quality of life (HRQoL) and adaptive function.

    Time frame: 11 years ± 1 year

  5. Risk Stratification Models

    Develop risk stratification models for 1) cardiac outcomes, 2) transplant-free survival, and 3) neurodevelopmental outcomes.

    Time frame: 11 years ± 1 year to 16 years

  6. Biospecimens

    Collect specimens from subjects and their parents to further develop the biologic specimen repository.

    Time frame: 11 years ± 1 year to 16 years

07

Results

Posted Nov 10, 2025
Limitations and caveats
We cannot exclude enrollment bias or survival bias.

Participant flow

Participant flow — Overall Study
MilestonemBTTSRVPAS
Started109128
Completed109128
Not completed00

Outcome measures

PrimaryRVEF at 10-12 Years on MRI

RV ejection fraction (RVEF) at 10-12 years, as measured by cardiac magnetic resonance (CMR).

Time frame:
assessed between 10-12 years of age, an average of 53.2 days from consent
Reported as:
Mean · percentage of blood pumped
RVEF at 10-12 Years on MRI
percentage of blood pumpedmBTTSRVPAS
RVEF at 10-12 Years on MRI52 ± 7.451 ± 9.6
SecondaryDeath or Cardiac Transplantation

The incidence of death or cardiac transplantation between those randomized to receive a RVPAS vs. a MBTS at the time of the Norwood operation.

Time frame:
11 years ± 1 year to 16 years

Results for this outcome have not been posted.

SecondaryThe Exercise Tolerance Between Those Randomized to a RVPAS vs. a MBTS.

Exercise capacity: Maximal Oxygen Consumption (VO2max), maximal work rate, and anaerobic threshold

Time frame:
11 years ± 1 year to 16 years

Results for this outcome have not been posted.

SecondaryAtrial and Ventricular Arrhythmias

The incidence of arrhythmias between those randomized to a RVPAS vs. a MBTS.

Time frame:
11 years ± 1 year to 16 years

Results for this outcome have not been posted.

SecondaryThe Neurodevelopmental Outcomes at 11 Years of Age in Those Randomized to a RVPAS vs. a MBTS

Achievement, as measured by the Wechsler Individual Achievement Tests (WIAT) (Math and Reading); Intelligence, as measured by the Wechsler Intelligence Scale for Children (WISC); Other domains of neurodevelopmental function including assessment of language, executive function, visual spatial skills, motor function, memory, social skills, behavior, health-related quality of life (HRQoL) and adaptive function.

Time frame:
11 years ± 1 year

Results for this outcome have not been posted.

SecondaryRisk Stratification Models

Develop risk stratification models for 1) cardiac outcomes, 2) transplant-free survival, and 3) neurodevelopmental outcomes.

Time frame:
11 years ± 1 year to 16 years

Results for this outcome have not been posted.

SecondaryBiospecimens

Collect specimens from subjects and their parents to further develop the biologic specimen repository.

Time frame:
11 years ± 1 year to 16 years

Results for this outcome have not been posted.

Adverse events

Collected over through study completion, an average of 5.3 years from consent. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mBTTS3/109 (2.8%)0/109 (0%)0/109 (0%)
RVPAS3/128 (2.3%)0/128 (0%)0/128 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)mBTTSRVPASTotal
<=18 years109128237
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)mBTTSRVPASTotal
Female474693
Male6282144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mBTTSRVPASTotal
Hispanic or Latino142741
Not Hispanic or Latino95100195
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)mBTTSRVPASTotal
White95106201
Non-White132134
Missing112
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Miller TA, Sharma B, Gongwer R, Trachtenberg FL, Newburger JW, Goldberg CS, Gustafson KE, Gaynor JW, Votava-Smith JK, Lambert LM, Sananes R, Kral MC, Tsang R, Heinrich KP, Cnota J, Shah A, Ilardi D; Pediatric Heart Network Investigators. Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network's Single Ventricle Reconstruction Trial. Circulation. 2025 Oct 28;152(17):1246-1261. doi: 10.1161/CIRCULATIONAHA.125.074523. Epub 2025 Jul 17. PubMed 40671650 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Oct 2020 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2025, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 28, 2015
Start
Jun 2015
Primary completionActual
Oct 2020
CompletionEst.
Dec 2025
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02455531
Lead sponsor
Carelon Research
Responsible party
Sponsor
First posted
May 28, 2015
Start date
Jun 2015
Primary completion
Oct 2020
Completion
Dec 2025 (estimated)
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion